L bioreliance corp:1108045 [14-042863]
Ended Awarded Last action
- Contract number
- HHSN26100013
- Awardee
-
Bioreliance Corporation UEI H3KAG9A26K77 Part of Sigma-Aldrich Corporation
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $91,832
Award facts
- Opportunity
-
- N02RC3600485 Solicitation number
- Biosafety Testing of GMP Master Cell Banks (MCB) and Retroviral Vectors for NCI Clinical Trials Award Notice · Posted Mar 7, 2013
- Contract value 100% obligated
- $91,832.29 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541380 Testing Laboratories and Services
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Rockville, MD 20850, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $91,832 |
About this award
The National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, awarded a $91,832.29 firm fixed-price delivery order to Bioreliance Corporation, a foreign-owned for-profit organization. The contract, which has no set-aside designation, is for Bioreliance's Life Sciences Services division to provide a range of specialized testing services, including endotoxin, sterility, and general safety testing, in support of investigational new drug applications. Bioreliance's parent company is Sigma-Aldrich Corporation, a major supplier of laboratory chemicals and materials. This contract award demonstrates Bioreliance's expertise and role in supporting government health initiatives through microbiological examinations, bioburden testing, and other safety assessments crucial for pharmaceutical and biotechnology research and development.
Quick answers
Who was awarded contract HHSN26100013?
HHSN26100013 was awarded to Bioreliance Corporation by National Cancer Institute (National Institutes of Health) on June 9, 2014.
How much is contract HHSN26100013 worth?
The government has obligated $91,832 on HHSN26100013.
Is contract HHSN26100013 an order under another contract?
Yes. HHSN26100013 is a delivery order under HHSN261201300026I, an indefinite delivery contract.
Was contract HHSN26100013 competed?
The extent of competition for HHSN26100013 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award